(1→3)β-<scp>d</scp>-Glucan Assay Positivity in Patients with <i>Pneumocystis (carinii) jiroveci</i> Pneumonia
Authors: Francisco M. Marty, Sophia Koo, Julie Bryar, Lindsey R. Baden
Journal: Annals of Internal Medicine (2007)

Letters3 July 2007(1→3)β-d-Glucan Assay Positivity in Patients with Pneumocystis (carinii) jiroveci PneumoniaFrancisco M. Marty, MD, Sophia Koo, MD, Julie Bryar, BA, and Lindsey R. Baden, MDFrancisco M. Marty, MDFrom Brigham and Women's Hospital, Boston, MA 02115., Sophia Koo, MDFrom Brigham and Women's Hospital, Boston, MA 02115., Julie Bryar, BAFrom Brigham and Women's Hospital, Boston, MA 02115., and Lindsey R. Baden, MDFrom Brigham and Women's Hospital, Boston, MA 02115.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-1-200707030-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Measurement of serum (1→3)β-d-glucan (β-glucan) is now available in the United States as a diagnostic aid for invasive fungal infections in high-risk patients (1, 2). β-Glucan is a cell-wall component of most pathogenic fungi, including Pneumocystis jiroveci (formerly P. carinii) (3). Serum β-glucan positivity in patients with Pneumocystis (carinii) jiroveci pneumonia (PCP) has been reported in Japan (4, 5). Whether the assay licensed in the United States (Fungitell, Associates of Cape Cod, Falmouth, Massachusetts) is reactive in patients with PCP is unknown (1, 2).Objective: To report the results of serum β-glucan testing among patients with a confirmed diagnosis ...References1. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199-205. [PMID: 15307029] CrossrefMedlineGoogle Scholar2. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1→3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-9. [PMID: 16080087] CrossrefMedlineGoogle Scholar3. Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool. 1989;36:21S-22S. [PMID: 2785184] CrossrefMedlineGoogle Scholar4. Shimizu A, Oka H, Matsuda T, Ozaki S. (1→3)-beta-d glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol. 2005;23:678-80. [PMID: 16173245] MedlineGoogle Scholar5. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) beta-d-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol. 1996;3:197-9. [PMID: 8991635] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Brigham and Women's Hospital, Boston, MA 02115.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySerum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCRDetecting Invasive Fungal Disease in Surgical Patients: Utility of the (13)- β- d -Glucan AssayPneumocystis PneumoniaCell‐free DNA next‐generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal diseaseInfections in CancerUse of 1,3-β-D-glucan in invasive fungal diseases in hematology patientsUsefulness of 1,3 Beta-d-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii PneumoniaMicrobiologic Diagnosis of Lung InfectionPneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factorsEmerging Issues With Diagnosis and Management of Fungal Infections in Solid Organ Transplant RecipientsPulmonary Manifestations of Human Immunodeficiency Virus InfectionPneumocystis Pneumonia in Human Immunodeficiency Virus–infected Adults and Adolescents: Current Concepts and Future DirectionsPneumonia in the immunocompromised hostNew Developments in Diagnostics and Management of Invasive CandidiasisClinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patientsDetection of (1, 3)-β-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hostsPneumocystis PneumoniaAccuracy of β -D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysisRecent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adultsNon-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity?Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors(1,3)- -D-Glucan as a Prognostic Marker of Treatment Response in Invasive CandidiasisProspective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal diseaseThe role of the clinical microbiology laboratory in solid organ transplantation programsInfections in Leukemia and Hematopoietic Stem Cell TransplantationA successful diagnostic case of Pneumocystis pneumonia by the loop-mediated isothermal amplification method in a patient with dermatomyositisPneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapiesPneumocystis jirovecii pneumonia in non-HIV-infected patientsPneumocystosisFungal infections in the critically illBlood (1->3)- -D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii PneumoniaElevated Serum Beta-d-Glucan Levels in Immunocompromised Children with Clinical Suspicion for Pneumocystis jirovecii PneumoniaSerum (1->3)- -D-Glucan Levels in Primary Infection and Pulmonary Colonization with Pneumocystis jiroveciiSerum (1 → 3)-β-d-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic valueUpdate on the diagnosis and treatment of Pneumocystis pneumoniaLes marqueurs biologiques dans le diagnostic et le suivi des infections fongiques invasivesRecomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010Detection and investigation of invasive mould diseaseClinical and Radiological Features of Acute-Onset Diffuse Interstitial Lung Diseases in Patients with Rheumatoid Arthritis Receiving Treatment with Biological Agents: Importance of Pneumocystis Pneumonia in Japan Revealed by a Multicenter StudyConserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murinaCase 35-2010Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapyDiagnostic challenges and recent advances in the early management of invasive fungal infectionsUnusual presentation of serum markers for suspected Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphomaPulmonary Manifestations of Human Immunodeficiency Virus InfectionMicrobiologic Diagnosis of Lower Respiratory Tract InfectionInfection in Renal Transplant RecipientsPneumocystis pneumonia in childrenPreemptive Antifungal TherapyCurrent status and future perspectives on molecular and serological methods in diagnostic mycologyAddition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphomaCan fungal biomarkers be used to improve antifungal therapy in the intensive care unit?Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and TreatmentAspergillosisPneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patientsFungal and Parasitic InfectionsPneumocystisInvasive fungal infections in cancer patientsRole of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosisUse of a Serum (1→3)‐β‐ d ‐Glucan Assay for Diagnosis and Follow‐Up of Pneumocystis jiroveci PneumoniaUse of a Serum β‐Glucan Assay for Diagnosis of HIV‐Related Pneumocystis jiroveci Pneumonia in Patients with Negative Microscopic Examination ResultsAdvances in the biology, pathogenesis and identification of Pneumocystis pneumoniaCurrent World Literature 3 July 2007Volume 147, Issue 1Page: 70-72KeywordsAntifungalsFeversImmunofluorescencePatientsPneumocystisPneumocystis carinii pneumoniaPneumoniaPulmonary diseases ePublished: 3 July 2007 Issue Published: 3 July 2007 CopyrightCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...